SEATTLE--(BUSINESS WIRE)--Cyrus Biotechnology, Inc., a Seattle-based biotech software company commercializing Rosetta, an advanced protein design platform, announced today the release of a novel Antibody Structure Prediction Software tool as part of its Cyrus Bench® platform.
“Antibodies make up the majority of Biologics, and now Cyrus users can model new antibodies in Bench®,” said Cyrus CEO Dr. Lucas Nivon. “Antibody modeling in Rosetta was pioneered by a number of laboratories, especially that of Dr. Jeffrey Gray at Johns Hopkins University, but those methods have remained difficult to access. Our new offering makes these applications significantly more robust and easier to use, so both laboratory biochemists and antibody engineers can rely on them.”
Rosetta software is the world leader in protein modeling and design. Now, the most up-to-date protocols in Rosetta for antibody modeling are available in Bench®, facilitating work on a wider variety of common monoclonal antibody engineering problems. When combined with Cyrus’ protein modeling tools for predicting how protein mutations affect stability and affinity, these antibody prediction tools make possible complex workflows for improving efficacy or reducing potential liabilities in candidate antibody biologics.
The Rosetta antibody tools, successfully validated in the Antibody Modeling Assessment (AMA-II), have now been extended to accept a broader range of inputs without user intervention. Cyrus’ implementation uses machine learning to improve the accuracy of the antibody structure prediction workflow.
The new antibody homology modeling software is now available to subscribers to Cyrus Bench® and to new customers who subscribe to the Cyrus Bench® suite of tools.
Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering Cyrus Bench®, a SaaS platform for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus Bench® is based on the Rosetta software from Prof. David Baker’s laboratory at the University of Washington, the most powerful protein engineering software available. Cyrus customers include 10 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.